Hemab Therapeutics Holdings, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Hemab Therapeutics Holdings, Inc. filed its Q2 2026 Form 10-Q, detailing continued investment in R&D, progress in clinical trials for sutacimig and HMB-002, and a substantial cash position post-IPO.